Project documents | Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578] | Guidance | NICE

Documents

Documents created during the development process.

Notes

To appraise the clinical and cost effectiveness of Avapritinib within its marketing authorisation for treating systemic mastocytosis ID6578

Invitation to participate

Final scope (PDF 141 KB)

Published:

23 September 2025
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 460 KB)

Published:

23 September 2025
Equality impact assessment (scoping) (PDF 120 KB)

Published:

23 September 2025
Final stakeholder list (PDF 152 KB)

Published:

23 September 2025

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Provisional stakeholder list post referral (PDF 144 KB)

Published:

05 August 2025
Draft scope post referral (PDF 147 KB)

Published:

05 August 2025